Best Practices for Informed Consent and Assent in Pediatric and Geriatric Clinical Trials

Introduction to Consent in Age-Specific Clinical Trials

Informed consent is a foundational ethical and legal requirement in clinical research. It ensures that participants—or their legal representatives—understand the nature, risks, and benefits of the trial before agreeing to participate. In pediatric and geriatric clinical trials, the consent process must be adapted to the specific cognitive, emotional, and situational needs of these vulnerable populations.

For pediatric participants, this often includes obtaining assent from the child in addition to formal consent from a parent or legal guardian. In geriatric trials, special considerations are needed for participants with cognitive decline, hearing impairments, or complex medical conditions that could impact comprehension. Regulatory frameworks such as ICH E6(R2) and ICH E11 provide guidance on ensuring the consent process is appropriate, transparent, and ethically sound.

Informed Consent for Pediatric Trials

Children cannot legally provide consent, so responsibility lies with a parent or legal guardian. However, ethical guidelines emphasize involving the child through an assent process appropriate to their developmental stage. Assent typically includes a simplified explanation of the trial, its procedures, potential discomforts, and the voluntary nature of participation.

• For children under 7 years: Use pictures, short sentences, and analogies to familiar experiences.
• For ages 7–12: Offer more detailed explanations, answer questions, and ensure comprehension.
• For adolescents: Provide information similar to that given to adults, supplemented with youth-friendly materials.

Example: In a pediatric vaccine study, children were shown illustrated storybooks explaining what would happen during each visit, which improved cooperation and reduced anxiety.

Informed Consent for Geriatric Trials

In elderly populations, informed consent must address sensory impairments, cognitive limitations, and potential caregiver involvement. Large-print forms, audio recordings, and simplified language can improve understanding. When participants lack decision-making capacity, consent may be obtained from a legally authorized representative (LAR) in accordance with national regulations.

Example: In a geriatric Alzheimer’s trial, consent discussions were conducted in the presence of both the participant and their caregiver, with frequent pauses for comprehension checks.

Table: Consent Adaptations for Pediatric and Geriatric Trials

Role of Caregivers in the Consent Process

Caregivers are often central to ensuring that consent is informed and sustained throughout the trial. In pediatric trials, parents act as advocates for the child’s welfare, while in geriatric trials, caregivers may provide essential support for understanding and decision-making. Engaging caregivers early and providing them with clear, accessible information fosters trust and compliance.

In long-term studies, re-consent may be necessary if there are protocol amendments or significant new findings. Caregivers should be kept informed through newsletters, meetings, and direct communication from trial staff.

Use of Multimedia and Technology in Consent

Modern consent processes increasingly use multimedia tools to enhance comprehension. Interactive videos, animations, and touchscreen apps can explain complex procedures in simpler terms. This approach benefits both children, who may learn visually, and elderly participants, who may need repeated exposure to the information.

Example: A pediatric asthma trial used animated videos to explain inhaler use, while a geriatric cardiac trial provided tablet-based consent forms with voiceover narration in multiple languages.

Ethical and Regulatory Oversight of Consent

Ethics committees and institutional review boards (IRBs) closely scrutinize consent materials for clarity, accuracy, and cultural appropriateness. They also verify that the consent process allows adequate time for participants or guardians to ask questions and consider their decision without pressure.

ICH guidelines require that the consent process be an ongoing dialogue, not a one-time event. This is particularly important in trials involving children and older adults, where changes in maturity or cognitive status may necessitate reassessment of consent.

Addressing Language and Cultural Barriers

Language and cultural differences can create misunderstandings that undermine informed consent. Translating consent forms into the participant’s preferred language, using interpreters, and incorporating culturally relevant examples can improve comprehension. For indigenous populations or immigrant communities, involving community leaders in the consent process may also enhance trust.

Example: In a pediatric oncology trial involving a multi-ethnic population, consent materials were translated into five languages, and bilingual staff were available during enrollment visits.

Case Study: Pediatric Diabetes Trial

In a multi-center pediatric diabetes trial, researchers implemented a dual-consent model—written parental consent plus child assent via a game-based app. The app explained trial procedures through interactive storytelling, resulting in a 95% comprehension rate among participants aged 8–12. Feedback from parents indicated increased confidence in their child’s understanding of the study.

Case Study: Geriatric Hypertension Trial

A hypertension trial for participants aged 75+ faced challenges with informed consent due to hearing impairments and cognitive decline. Researchers adapted by conducting one-on-one consent sessions in quiet rooms, using visual aids, and involving caregivers. They also allowed participants to take home consent materials for review before signing, which improved retention and satisfaction.

Maintaining Ongoing Consent

Ongoing consent involves checking in with participants regularly to confirm willingness to continue. In pediatric trials, this may mean reaffirming assent as children mature. In geriatric trials, it may involve confirming consent if health status changes. This ongoing process respects autonomy and ensures ethical compliance throughout the study.

Example: In a five-year geriatric dementia prevention trial, consent reaffirmation occurred annually, with caregivers present to witness and participate in the discussion.

Conclusion

Informed consent and assent in pediatric and geriatric clinical trials demand thoughtful adaptation to meet the needs of vulnerable participants. Clear communication, caregiver engagement, multimedia tools, and culturally sensitive materials all play vital roles in ensuring that consent is truly informed. By prioritizing comprehension and autonomy, researchers can uphold ethical standards and build trust with participants and their families, ultimately contributing to higher trial quality and compliance.

How CRCs Facilitate Patient Consent and Long-Term Retention in Clinical Trials

Introduction: The CRC as a Patient Advocate

The Clinical Research Coordinator (CRC) is often the first and most consistent point of contact for clinical trial participants. Their responsibilities go beyond scheduling visits and collecting data—they play a central role in gaining informed consent and keeping subjects engaged throughout the study. These functions are essential for regulatory compliance and the overall success of the trial.

This tutorial explores how CRCs manage the dual responsibility of facilitating proper informed consent and minimizing patient dropout rates. It offers best practices, regulatory references, and actionable tips for enhancing the patient experience in clinical research settings.

Step-by-Step: Facilitating the Informed Consent Process

Gaining informed consent is more than obtaining a signature—it’s a regulated communication process governed by ICH E6(R2), FDA regulations, and institutional ethics standards. CRCs must:

• ✅ Provide the latest IRB/EC-approved Informed Consent Form (ICF)
• ✅ Explain the study’s purpose, procedures, risks, and benefits in layman’s language
• ✅ Ensure that the subject has sufficient time to review and ask questions
• ✅ Confirm that the decision to participate is voluntary and without coercion
• ✅ Document the consent process appropriately and file all signed forms

The CRC must also verify that all signatures and initials are present and dated correctly. Errors in the ICF are among the top five most frequent FDA inspection findings. For re-consenting, CRCs must track version numbers and obtain fresh signatures for amended protocols or new safety data.

Building Rapport to Increase Consent Rates

Subjects are more likely to consent and stay in trials when they feel understood and supported. CRCs build trust through:

• ✅ Active listening and addressing concerns empathetically
• ✅ Sharing real-life analogies to explain trial terminology
• ✅ Providing translated ICFs and interpreter support where needed
• ✅ Giving honest answers about side effects, trial duration, and follow-up expectations

Rather than “selling the study,” CRCs must adopt a patient-centered approach. In trials involving vulnerable populations (e.g., pediatrics, oncology), rapport building becomes even more critical. Ethics committees often assess CRC-subject communication quality during audits or routine inspections.

Common Pitfalls and GCP Noncompliance

CRCs must avoid several errors during the consent process, such as:

• ❌ Using expired or unapproved ICF versions
• ❌ Taking consent after the screening procedure has begun
• ❌ Missing required witness signatures for illiterate participants
• ❌ Failing to document subject questions or re-consent discussions

To prevent these issues, many sites use ICF checklists and consent version logs. Some also video record the process (if permitted), especially in high-risk or high-value studies. For sample SOPs and compliance templates, refer to PharmaSOP.

Retention Begins at Enrollment

Once the patient consents, retention becomes the new challenge. The CRC must:

• ✅ Ensure the subject knows the visit schedule, reimbursement policy, and contact info
• ✅ Provide written instructions for pre-visit requirements (e.g., fasting, medication washout)
• ✅ Collect alternative contact information (permitted by privacy policy)

First impressions last. Subjects who feel supported at the start are more likely to complete the trial. CRCs can provide welcome kits, contact cards, or mobile notifications to keep communication channels open.

Proven Strategies to Reduce Dropout Rates

CRCs play a critical role in implementing retention strategies that align with ethical and regulatory standards. These include:

• ✅ Sending personalized visit reminders via call, SMS, or email
• ✅ Providing flexible scheduling and transport reimbursement
• ✅ Creating a comfortable clinic environment for long visits
• ✅ Regularly checking for emerging concerns or adverse effects

In long-term studies (e.g., diabetes or cancer trials), CRCs may maintain a patient engagement log that tracks emotional cues, family involvement, or compliance trends. High-performing sites often assign retention scores and discuss patient feedback in weekly meetings.

Handling Patient Withdrawal Respectfully

No matter how diligent the CRC is, some patients will choose to withdraw. The role of the CRC in such cases is to:

• ✅ Document the reason for withdrawal without pressuring the subject
• ✅ Notify the PI and sponsor per SOP
• ✅ Ensure that any final assessments or safety follow-ups are conducted if permitted
• ✅ Archive all documents and update the trial database accordingly

Subjects must be informed during consent that they can withdraw at any time. Respecting this right builds public trust in research and reduces reputational risk for the site and sponsor.

Using Technology to Improve Consent and Retention

Modern clinical trials are increasingly adopting digital tools to improve the patient experience:

• ✅ eConsent Platforms: Allow remote consent with version control and audit trails
• ✅ Mobile Apps: Enable reminders, protocol guidance, and symptom reporting
• ✅ Telehealth: Used for follow-up visits, reducing patient burden

CRCs must receive adequate training in these platforms and maintain backup processes in case of technical failure. Regulatory bodies like FDA and EMA have issued guidance on using digital consent in decentralized trials.

Monitoring and Reporting Retention Metrics

Sites are increasingly judged based on subject retention performance. CRCs are expected to:

• ✅ Track subject visit completion rate and dropout reasons
• ✅ Maintain a retention dashboard for internal quality checks
• ✅ Discuss high-risk subjects during monitoring visits

Dropout rates above 20% can trigger sponsor interventions or audits. CRCs who maintain transparent logs and proactive communication are often acknowledged in final trial reports.

Conclusion

The CRC’s influence on patient consent and retention cannot be overstated. From the initial ICF discussion to the final study visit, CRCs act as liaisons, educators, and advocates. Their communication style, organizational systems, and empathy define the subject’s trial experience—and often, the trial’s success.

By investing in structured consent processes, personalized retention strategies, and ongoing training, CRCs can meet both ethical obligations and operational goals. In today’s patient-centric trial landscape, retention is not just about follow-up—it’s about trust, clarity, and connection.

References:

• PharmaSOP: Blockchain SOPs for Pharma
• FDA Guidance on Informed Consent
• EMA Informed Consent Guidelines
• PharmaValidation: GxP Blockchain Templates

How to Document the Informed Consent Process According to GCP Guidelines

Proper documentation of the informed consent process is critical for ensuring ethical compliance, patient safety, and regulatory audit readiness in clinical trials. Good Clinical Practice (GCP) guidelines, including ICH-GCP E6(R2), outline the specific documentation standards investigators must follow. This tutorial provides step-by-step guidance on how to document informed consent in line with global GCP requirements and sponsor expectations.

Why Consent Documentation Matters:

Accurate and complete documentation proves that informed consent was obtained ethically and legally. Inadequate records can lead to inspection findings, data exclusion, and even study termination.

• Ensures participant understanding and voluntariness
• Confirms use of approved ICF versions
• Enables traceability and regulatory review
• Supports data integrity and trial credibility

Documentation requirements apply to both paper-based and electronic consent systems as mandated by USFDA, CDSCO, and other agencies.

Key GCP Elements to Be Documented:

• Correct version and date of the ICF used
• Date consent was obtained
• Participant and investigator signatures
• Details of the person who obtained consent
• Language of the consent form
• Use of impartial witness if required
• Participant’s opportunity to ask questions

This documentation must align with your site’s GMP SOPs for informed consent procedures and the site delegation log.

Consent Process Documentation in Source Notes:

The source documentation should reflect the consent process clearly. The note should include:

• Date and time of consent discussion

<liConfirmation that the ICF was reviewed with the participant

• That the participant was given sufficient time to decide
• Confirmation of questions asked and answered
• Verification of the signed, dated, and witnessed ICF
• Documentation of language and translator/witness (if applicable)

Example entry: “On [date], participant reviewed ICF v3.0 (dated [X]) with Dr. Y. All questions were answered. Subject signed and dated the ICF; copy provided. Consent obtained in Hindi with witness present.”

Maintaining Consent Documents in the Investigator Site File (ISF):

Signed consent forms must be stored securely in the ISF. Best practices include:

• Filing the original signed ICF in chronological order
• Keeping a master log of all ICF versions and approval dates
• Cross-referencing with participant ID and screening logs
• Protecting confidentiality and access control

These practices align with clinical trial documentation expectations and GCP inspections.

Version Control and Audit Trail:

Consent version control is vital. Investigators must ensure:

• The correct ICF version is used for each participant
• Old versions are not used once superseded
• All amended ICFs are Ethics Committee (EC) approved
• Signed revised consent is documented for re-consented participants

Maintain an Informed Consent Version Log and update the validation master plan accordingly.

Handling Special Consent Situations:

1. Illiterate Participants:

• ICF should be read aloud in the participant’s language
• An impartial witness must be present throughout the discussion
• Consent must be documented with participant’s thumb impression and witness signature

2. Verbal Consent:

• Allowed only in exceptional EC-approved cases
• Must be accompanied by detailed notes and witness signatures
• Written documentation must follow as soon as possible

3. Electronic Consent (eConsent):

If using eConsent tools, ensure:

• Electronic signature validity is confirmed
• System has audit trails and secure access
• Participant receives a downloadable or printed copy

Ensure the platform follows GMP guidelines and is validated under 21 CFR Part 11.

Staff Training and Delegation:

Only trained and delegated personnel may obtain and document consent. Keep training records that confirm staff understand:

• Consent documentation requirements
• Version control and approval processes
• How to handle special populations and translations
• Documentation in source and regulatory files

Training logs should be kept updated and audited during monitoring visits.

Common Audit Findings and How to Avoid Them:

• Missing participant or investigator signatures
• Incorrect ICF version used
• No record of re-consent for protocol amendments
• Improperly documented consent for illiterate participants
• Unsigned witness section when required

Use consent checklists to avoid omissions and ensure consistent site practices per pharma regulatory requirements.

Checklist for Consent Documentation per GCP:

1. Obtain latest EC-approved ICF version
2. Document full consent process in source notes
3. Verify and file signed ICF in the ISF
4. Record witness or translator involvement if needed
5. Update consent logs and screening logs
6. Ensure consistency across monitoring visits and audits

Conclusion:

Documenting the informed consent process is not just about obtaining a signature—it is about capturing the entire communication, understanding, and agreement process in a verifiable, compliant manner. By adhering to ICH-GCP, national regulations, and sponsor SOPs, investigators can ensure that participant rights are respected and trial data remains valid. Meticulous documentation reinforces trial integrity, safeguards against regulatory findings, and upholds ethical standards in every clinical study.

How to Evaluate Patient Understanding Before Informed Consent in Clinical Trials

Informed consent in clinical trials is only valid if the participant truly understands what the study involves. It is not enough to simply present information—the responsibility lies with the research team to assess and confirm patient comprehension before obtaining consent. This tutorial explores practical tools, regulatory expectations, and step-by-step strategies to evaluate patient understanding ethically and effectively.

Why Assessing Comprehension is Crucial:

The ethical foundation of informed consent lies in the participant’s informed, voluntary decision. Without adequate comprehension, consent becomes meaningless. Ensuring understanding helps:

• Protect vulnerable populations from unintended risks
• Reduce protocol deviations due to misunderstandings
• Strengthen regulatory compliance and audit readiness
• Align with GMP quality control and ICH-GCP standards

Regulatory Expectations for Comprehension Assessment:

According to USFDA, ICH-GCP E6, and national regulations like CDSCO and EMA guidelines, investigators must not only deliver information but confirm that participants understand it. The consent process should be documented and validated through appropriate methods.

Key Concepts to Be Understood by Participants:

Participants should clearly grasp the following before signing the informed consent form (ICF):

1. Purpose of the trial and their role
2. Study procedures and duration
3. Potential risks and expected benefits
4. Alternatives to participation
5. Voluntary nature of participation and withdrawal rights
6. Confidentiality and data protection
7. Whom to contact in case of questions or injury

These elements are also part of the pharmaceutical SOP checklist for informed consent procedures.

Methods to Assess Comprehension Before Consent:

Here are validated techniques that can be integrated into your clinical trial consent process:

1. Teach-Back Method:

Ask participants to explain in their own words what they have understood. This interactive method highlights gaps in comprehension and provides immediate feedback.

• “Can you tell me what this study is about?”
• “What would you do if you wanted to stop the study?”
• “What are the risks we talked about?”

Reinforce information wherever there’s confusion, then reassess until clarity is achieved.

2. Comprehension Questionnaires:

Develop short quizzes based on the ICF content. These can be paper-based or digital and should include:

• Multiple-choice or true/false items
• Scenarios requiring application of understanding
• Questions on key rights and responsibilities

Responses should be reviewed by qualified personnel listed in the delegation log.

3. Role-Play and Interactive Scenarios:

This is especially useful in low-literacy populations or pediatric studies. Participants can act out scenarios that test their understanding of trial actions and consequences.

4. Observation and Non-Verbal Cues:

Assess body language, hesitations, or signs of confusion. Participants who nod without asking questions may not fully understand. Use prompts to encourage open conversation.

Special Considerations for Vulnerable Populations:

When dealing with children, elderly patients, or individuals with cognitive limitations:

• Use age-appropriate explanations and assent forms
• Confirm comprehension through guardians or legal representatives
• Follow national ethical standards like those outlined by TGA and ICMR

These additional steps help ensure that informed consent is truly informed, not coerced or miscommunicated.

Documenting Comprehension Assessment:

Proper documentation is as critical as the assessment itself. Your trial records should reflect:

• Assessment method used (e.g., teach-back, quiz)
• Date and time of discussion
• Person conducting the assessment
• Any re-education provided and its outcome
• Signed witness statements (if applicable)

These records should be retained in the Investigator Site File (ISF) and monitored for audit readiness.

When to Delay Consent Signing:

If comprehension is found to be insufficient:

1. Pause the process and schedule a follow-up session
2. Involve caregivers or legal representatives for better communication
3. Do not proceed with signing the ICF until clarity is established

Consent obtained without understanding is not legally or ethically valid.

Training Staff for Effective Assessments:

All team members involved in the consent process should be trained in:

• Effective communication and listening skills
• Handling questions with empathy and clarity
• Using standardized comprehension tools
• Documenting discussions as per validation protocols

Mock role-plays and scenario-based GCP training are useful in building these skills.

Using Electronic Tools to Aid Comprehension:

With the advent of eConsent platforms, comprehension can now be measured through:

• Interactive modules and videos with pause-and-check questions
• Real-time scoring of quiz responses
• Auto-flagging participants with low comprehension

Ensure that your system complies with pharma regulatory compliance and data privacy standards.

Best Practices for Sponsors and Ethics Committees:

Sponsors should support sites by:

• Providing validated tools and ICF templates
• Encouraging inclusion of comprehension metrics in monitoring plans
• Instructing monitors to verify participant understanding during site visits
• Including comprehension assessments in SOP writing in pharma

Conclusion:

Assessing comprehension is not an optional add-on—it is an ethical and regulatory imperative. By incorporating standardized, participant-centric assessment methods, clinical trial teams can ensure that consent is genuinely informed. This safeguards participant rights, improves trial quality, and aligns with global regulatory expectations.

Informed Consent Documentation Variations Across ASEAN Clinical Trials

Informed consent is a cornerstone of ethical clinical research, ensuring participants understand the risks, benefits, and purpose of a study before voluntarily agreeing to participate. In the ASEAN region, informed consent requirements are influenced by each country’s regulations, cultural considerations, and language diversity. Understanding these differences is vital for sponsors, clinical investigators, and regulatory professionals working across multiple jurisdictions.

This article provides a tutorial-style breakdown of the major variations in informed consent documentation across ASEAN countries, with a focus on ethical standards, formatting, language translation, audiovisual requirements, and institutional review board (IRB) expectations. Special attention is given to vulnerable populations, including children and those with limited literacy.

Core Elements of Informed Consent:

According to ICH-GCP and CDSCO standards, the following components are typically required in any informed consent form (ICF):

• Purpose of the study
• Study procedures and duration
• Potential risks and benefits
• Voluntary participation and right to withdraw
• Confidentiality and data protection
• Compensation for injury
• Contact information for inquiries

Country-Specific Consent Documentation Requirements:

1. Singapore:

Governed by the Health Sciences Authority (HSA) and NHG Domain Specific Review Board, Singapore mandates consent forms be written in layperson language (grade 6–8 readability). English is primarily used, but translated versions in Mandarin, Malay, or Tamil are often required depending on the study population.

2. Malaysia:

Malaysia’s Medical Research and Ethics Committee (MREC) insists that ICFs be provided in both English and Bahasa Malaysia. The form must include sections for audio-visual consent documentation when applicable. Templates provided by the Ministry of Health are often used to maintain uniformity.

3. Thailand:

The Thai FDA and local IRBs require ICFs to be in Thai and validated for cultural appropriateness. Consent forms for illiterate participants must be read aloud and documented with thumbprint and witness signature. Assent forms for minors aged 7–17 are mandatory in pediatric trials.

4. Indonesia:

Regulated by Badan POM, Indonesia mandates ICFs in Bahasa Indonesia and requires approval from both the central ethics committee and institutional IRBs. Translations must be certified, and additional forms are required when guardians or legal representatives provide consent.

5. Philippines:

Guided by the Philippine Health Research Ethics Board (PHREB), consent documents must be in English and the local dialect (Tagalog, Cebuano, etc.). If participants cannot read, an impartial witness must sign the consent document. Audiovisual documentation is mandatory for clinical trials involving vulnerable subjects.

6. Vietnam:

The Ministry of Health requires ICFs in Vietnamese, and sponsors must ensure linguistic accuracy. IRBs often request both paper and digital versions of consent documents. Special provisions are made for subjects who are illiterate, elderly, or cognitively impaired.

Key Documentation Differences in ASEAN Trials:

1. Language Translation: Most ASEAN countries require the ICF in both English and the local language. Certified translations are preferred.
2. Witness Requirements: For non-literate populations, a neutral third-party witness is mandatory in Thailand, Indonesia, and the Philippines.
3. Audio-Visual Recording: Malaysia and the Philippines mandate AV recordings for vulnerable populations, especially in high-risk trials.
4. Assent Documentation: Assent forms for minors are explicitly required in Thailand and the Philippines, and encouraged elsewhere.
5. IRB Templates: Malaysia and Vietnam often require the use of IRB-provided ICF templates to standardize content and language.

Special Considerations for Vulnerable Populations:

ASEAN countries are particularly cautious about enrolling vulnerable subjects such as minors, pregnant women, or mentally impaired individuals. In such cases:

• Guardianship documentation is reviewed
• Assent is required from capable minors
• Ethics committees closely review consent content and delivery method

In countries like Vietnam, additional local consent forms may be required for specific disease studies (e.g., TB or HIV).

Common Mistakes and Solutions:

• Omitting Translations: Ensure all ICFs are bilingual with certified translations for target populations.
• Improper Formatting: Follow country-specific templates where available and review IRB SOPs.
• Lack of AV Recording: Confirm whether vulnerable groups require audio-video consent procedures and document accordingly.
• No Assent Process: Include assent procedures and forms for minors and cognitively aware adolescents.

Ethics Committee Review of Informed Consent:

Across ASEAN, ethics committees have the final say in approving the language, structure, and process of obtaining informed consent. Multiple review rounds may be required to address local norms, readability, and regulatory compliance.

For example, the Philippine IRB may insist that certain cultural expressions or superstitions be removed from translations to avoid participant confusion. In Thailand, trial sponsors are expected to submit a “Consent Process Flowchart” outlining how consent is obtained and documented.

Best Practices for Compliance and Quality:

• Use a Pharma SOP for informed consent tailored to each ASEAN country
• Maintain a library of IRB-approved ICF templates per language
• Ensure ongoing training for clinical site staff on GCP-compliant consent delivery
• Audit signed consent forms during monitoring visits
• Document AV consent sessions securely and in compliance with data protection laws

Regular updates based on Stability Studies and regulatory revisions help ensure informed consent materials reflect current science and ethical standards.

Conclusion:

While the ASEAN Clinical Trial Framework promotes harmonization, local regulatory nuances significantly impact how informed consent is documented. Awareness of these differences—and proactively designing consent procedures accordingly—is essential to maintain ethical standards and avoid regulatory delays. Sponsors should partner with local experts, ethics committees, and CROs familiar with regional consent expectations to streamline compliance and improve participant understanding across all ASEAN member states.